Articles tagged with Type 1 Diabetes
A new combined approach improves prediction of type 1 diabetes in high-risk children, allowing better risk counselling and early intervention. The test doubles the efficiency of newborn screening programmes to prevent life-threatening ketoacidosis.
Research suggests that bacterial infections, as indicated by antibiotic purchases, increase the risk of coronary heart disease in individuals with type 1 diabetes. Elevated levels of bacterial lipopolysaccharides also contribute to this increased risk.
Scientists at UCL have discovered new biomarkers that can identify people with Type 1 diabetes who are likely to respond to the immunotherapy drug Abatacept. The study found that certain immune cells, known as 'follicular helper T cells', play a key role in the disease.
A new drug candidate, SRI-37330, has been discovered to improve four detrimental characteristics of diabetes: high blood sugar, glucagon elevation, excessive glucose production by the liver, and fatty liver. The compound is non-toxic, orally bioavailable, and highly effective in human islets and mouse models.
A national cost-sharing cap on insulin can help reduce the financial burden on families of children and young adults with type 1 diabetes. The study found that approximately 60% of patients would benefit from a $25 cap, with average savings of almost $480 per year.
Joslin Diabetes Center researchers discover targeting renalase protein strengthens beta cells against stress and autoimmune attack. An FDA-approved drug, pargyline, is shown to protect human cells, potentially slowing disease progression in a clinical trial.
Case studies published by Physicians Committee for Responsible Medicine found that plant-based diets rich in whole carbohydrates improved health markers in individuals with type 1 diabetes. The diets led to decreased insulin needs, stabilized blood sugar control, and reduced cholesterol levels.
A new study found that children with newly-diagnosed type 1 diabetes have a distinct gut microbiome composition associated with poorer blood sugar control. The researchers used machine learning analysis and genetic analysis to identify this link, highlighting the importance of gut health in disease development.
Researchers found persistent DNA methylation changes in blood cells and stem cells associated with metabolic memory and future diabetic complications. The study provides evidence of a link between epigenetics, glycemic history, and complication development, offering potential biomarkers for early intervention and prevention.
Researchers found that Cyclocarya paliurus polysaccharide modulates the gut microbiota and improves metabolic pathways, leading to a reduction in serum glucose levels and alleviating type 2 diabetes symptoms. The study provides new insights into the use of dietary polysaccharides for preventing or intervening in T2DM.
Research found a significant increase in insulin pump use and a decline in diabetic nephropathy, while pre-pregnancy obesity rose. The percentage of mothers with excess weight gain during pregnancy also increased. Despite this, the prevalence of very large babies born remained the same.
A clinical trial found that reducing uric acid levels with the medication allopurinol did not slow the progression of kidney disease in people with type 1 diabetes. Despite a significant drop in uric acid levels, participants showed no improvement in their kidney function.
A Phase 2 study led by UB pediatric endocrinologist Teresa Quattrin shows that golimumab, an anti-TNF therapy, preserved beta-cell function and reduced injected insulin required in children and young adults with newly diagnosed Type 1 diabetes. The study demonstrated a higher C-peptide level in patients treated with golimumab compared ...
A recent study published in the New England Journal of Medicine found that teplizumab significantly delayed the onset of type 1 diabetes by three years compared to a placebo. The trial involved individuals at high risk of developing T1D, and those treated with teplizumab showed higher rates of insulin secretion and C-peptide levels.
A new genetic risk score has been found to be effective in diagnosing type 1 diabetes in Indians, even in its current form based on European data. Genetic differences between Indian and European populations suggest that the test could be further improved to enhance outcomes.
Researchers at Oregon Health & Science University have developed an AI algorithm that uses data from continuous glucose monitors and wireless insulin pens to provide guidance on adjustments. The algorithm, paired with a smartphone app called DailyDose, generated recommendations in agreement with physicians 67.9% of the time.
Research by the University of Sheffield reveals people with diabetes are at a greater risk of bone fractures, especially hip fractures. Severity and length of time living with the condition also increase this risk.
A new study finds that people with Type 1 diabetes spend an average of $2,500 a year on healthcare costs, with diabetes-related supplies costing more than insulin. The study also highlights the importance of automating glucose monitoring and insulin delivery for young children and adolescents with Type 1 diabetes.
The CORONADO study found that 1 in 10 COVID-19 patients with diabetes died within 7 days of hospital admission, and 1 in 5 were intubated and mechanically ventilated. Poorer blood sugar control did not impact patient outcomes, but the presence of diabetic complications and increasing age increased mortality risk.
A new study found that telehealth monitoring and technology can lead to better outcomes for patients with type 1 diabetes during the COVID-19 pandemic. By allowing for frequent insulin dose adjustments and improving glucose values, telehealth helped avoid hospital admissions for diabetic ketoacidosis.
A study funded by JDRF, ADA, and Helmsley found all human and analog insulins in US pharmacies contained the expected amount of active insulin, posing no safety risks for people with diabetes.
Researchers at Karolinska Institutet and the universities of Jyväskylä and Tampere have produced a vaccine that protects against all six known strains of Coxsackie B virus, which may play a role in triggering type 1 diabetes. The vaccine was tested in animal models and showed promise, with plans to conduct human clinical trials.
Researchers have developed a vaccine that protects against the Coxsackie B virus, which may play a role in triggering type 1 diabetes. The vaccine was shown to be highly immunogenic and protective in animal models and non-human primates.
Researchers screened 25,000 children in the Denver metro area and found that early detection can reduce incidence of diabetic ketoacidosis by 20%, leading to improved disease control and reduced healthcare costs. The study highlights the potential for screening to improve overall quality of life and reduce long-term health risks.
The Critical Path Institute (C-Path) has received a letter of support from the European Medicines Agency (EMA) to facilitate the development and validation of pancreatic islet autoantibodies as enrichment biomarkers for type 1 diabetes clinical trials. This collaboration aims to accelerate drug development in T1D by identifying patient...
Two case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in adults and infants during the pandemic. The technology showed improved outcomes with increased time-in-range, as patients received virtual management and dose adjustments.
Research from Joslin Diabetes Center found that autoantibodies against heart muscle proteins are associated with increased volume of the left ventricle, reduced pumping function, and higher risk of failure. The study suggests a novel process involving the heart linked to poor glycemic control in type 1 diabetes patients.
A recent study found that technology use by adults with type 1 diabetes is lower among African-American and Hispanic patients. The use of continuous glucose monitors (CGM) and continuous subcutaneous insulin infusion (CSII) devices was significantly lower in these groups, highlighting racial disparities in access to healthcare.
A study analyzing 6 million days of real-world data shows the MiniMed 670G system can maintain target glucose range of 70-180 mg/dL over 71% of the time. The AutoMode feature improves glycemic control, reducing low and high blood sugar episodes.
Researchers at St. Jude Children's Research Hospital created an 'atlas' of gene-regulatory mechanisms in immune cells that facilitate Type 1 diabetes. The study revealed a dual biological personality of T cells, enabling them to retain the ability to attack insulin-producing cells across successive generations.
Researchers at UW-Madison discovered that removing a specific gene from insulin-producing cells can prevent Type 1 diabetes in mice by allowing the cells to disguise themselves from immune cells. This genetic manipulation enabled the cells to evade an autoimmune response, leading to normal glucose levels and insulin production.
Research found that individuals with type 2 diabetes who participate in online support groups have worse health outcomes and higher levels of disease-related complications. In contrast, users with type 1 diabetes did not show a significant correlation between forum participation and health outcomes.
Research reveals that children diagnosed with type 1 diabetes under 7 years old have a different form of the condition compared to those diagnosed at 13 or above. The study proposes two distinct endotypes: T1DE1 and T1DE2, which could lead to new treatments and a potential cure for some people.
A large observational study of nearly 387,000 children found no association between rotavirus vaccination and the development of type 1 diabetes. Researchers noted limitations and potential confounding variables that may have affected results.
Researchers at Penn Medicine discovered that changes in DNA sequence can trigger chromatin misfolding in white blood cells, increasing the risk of developing Type 1 diabetes. The study found that these misfolded regions occur before the disease onset and may serve as a diagnostic tool.
Boston College biologist Emrah Altindis received a $300,000 grant from the G. Harold and Leila Y. Mathers Foundation to explore the role of gut microbes and viruses in triggering Type 1 diabetes. The research aims to understand molecular mimicry as a potential cause of the autoimmune disease.
The Juvenile Diabetes Research Foundation (JDRF) honored five researchers for their outstanding contributions to type 1 diabetes research, including breakthroughs in beta cell autoimmunity and immune therapies. The awards recognize significant progress toward curing T1D, with funded research totaling over $2.2 billion.
New research from the University of Colorado Anschutz Medical Campus suggests that changes in the environment may contribute to the rising incidence of type 1 diabetes. The study examined various environmental exposures and found that none of the associations were strong enough to explain the rapid increase alone.
Researchers identified growth differentiation factor 15 (GDF15) as a key player in delaying type 1 diabetes onset in diabetic mice. Treatment with GDF15 reduced development of diabetes by 53% in non-obese diabetic mice, providing a potential target for prevention and treatment.
A team of CHOP researchers has discovered a genetic signature that can help diagnose adult-onset 'type 1.5' diabetes, which shares characteristics with pediatric-onset type 1 diabetes. The finding could lead to more effective diagnostic methods and improve treatment outcomes for adults.
Researchers deciphered a mechanism impairing regulatory T cell differentiation and stability in type 1 diabetes. Inhibiting the miRNA142-3p molecule increased functional Tregs and reduced autoimmune activation.
Patients with type 1 diabetes and high lipoprotein(a) levels have a significantly higher risk of developing cardiovascular disease, including coronary artery disease and calcified aortic valve disease. High blood glucose levels are also associated with elevated lipoprotein(a) levels in this patient group.
A clinical trial is underway to study the efficacy of umbilical cord-derived mesenchymal stem cells as a potential therapeutic for new onset type 1 diabetes. The trial, funded by the NIH, aims to determine if systemic administration of these cells can reduce disease progression and preserve insulin secretion.
Researchers found that adjusting CGM alarm settings can inform patients about high or low blood sugar events early, enabling timely treatments. The study suggests simpler adjustments to these thresholds could lead to better management of hypo- and hyperglycemia for people with type 1 diabetes.
A three-year clinical study found that reducing uric acid levels with the generic drug allopurinol did not slow diabetic kidney disease progression in type 1 diabetes patients. The study's conclusions provided a clear answer to an important scientific question, while suggesting further research may be needed.
A multi-center trial found that the artificial pancreas system improved users' blood glucose control throughout the day and overnight, reducing hyperglycemia and hypoglycemia events. The study showed significant benefits of the new system over existing treatments, with no severe hypoglycemia events occurring in either group.
A new artificial pancreas system improved participants' blood glucose control throughout the day and overnight, reducing the risk of low blood sugar levels. The system's advanced algorithms and safety features enabled users to achieve near-normal blood sugar levels every morning.
A new artificial pancreas system improved blood glucose control throughout the day and overnight, reducing time in range for high and low glucose levels. The system also showed improvements in hemoglobin A1c and other measurements related to diabetes control compared to current technology.
A new study suggests that rotavirus infection may trigger the development of type 1 diabetes. Researchers found a significant decrease in the incidence of type 1 diabetes in Australian children under four years old after the introduction of rotavirus vaccination.
A new calculator developed by the University of Exeter will help clinicians classify patients with type 1 or type 2 diabetes, reducing complications and misdiagnosis. The calculator combines blood test results with age and BMI to provide a personalized medicine approach.
A study published by researchers from the Turku Bioscience Centre found changes in circulating molecules in the blood that may be new markers of type 1 diabetes. This discovery could provide an early window for intervention and prevention of the disease.
Patients with type 1 diabetes who experience hospitalizations for ketoacidosis or hyperglycemic comas have an increased risk of subsequent suicidal attempts. The risk is strongly associated, with a threefold increased risk for those with multiple hyperglycemic coma hospitalizations.
A Norwegian study found that a child's gluten intake at 18 months is associated with a 46% increased risk of developing type 1 diabetes for each extra 10g of gluten consumed. The mother's gluten intake during pregnancy was not linked to the risk.
Researchers found that carbohydrate content and meal type are the most important factors affecting carb-counting accuracy. Larger meals tend to have more errors, while smaller meals have fewer mistakes.
A highly predictive genetic risk score is being developed by Paul Tran to identify children at significant risk of developing type 1 diabetes. The algorithm uses a feedforward neural network to analyze thousands of gene variants associated with the disease, aiming to predict with five times better accuracy than current systems.
A new study by the University of Turku and Tampere University found that chronic enteroviral infection can modify broadly pancreatic cellular functions, including alterations in protein expression and secretion. The study suggests that such infections may have adverse health effects, particularly on the development of type 1 diabetes.
Researchers have identified microRNA-204 as a biomarker for early beta cell death in Type 1 diabetes, which can identify disease onset in children and adults with recent-onset Type 1 diabetes. Serum miR-204 levels were found to be elevated in individuals with Type 1 diabetes and inversely correlated with remaining beta-cell function.
Researchers at Scripps Research Institute have discovered a potential biological marker for early detection of type 1 diabetes using single-cell analysis of immune cells. The discovery could lead to earlier intervention and prevention of the disease, which affects over 1.25 million Americans.
A new study published in BMJ found that blood glucose levels between 48-52mmol/mol do not provide additional protection against organ damage, whereas levels below 48 do not offer further reduced risk. Patients with low HbA1c values need to monitor for excessively low glucose levels and fluctuations.
Researchers at MUSC have identified a specific lipoprotein phenotype associated with an increased risk of preeclampsia in pregnant women with type 1 diabetes. Monitoring these patients closely and taking proactive measures to keep their blood pressure down can help prevent the complication.